Clinical overlap between Alzheimer's disease (AD) and limbic‐predominant age‐related transactive response DNA binding protein 43 (TDP‐43) encephalopathy (LATE), combined with the absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. This evidence concerns the gene TARDBP and early-onset autosomal dominant Alzheimer disease.